Frontiers in Immunology (Nov 2022)

Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors

  • Ivan J. Cohen,
  • Fresia Pareja,
  • Nicholas D. Socci,
  • Ronglai Shen,
  • Ashley S. Doane,
  • Jazmin Schwartz,
  • Raya Khanin,
  • Elizabeth A. Morris,
  • Elizabeth J. Sutton,
  • Ronald G. Blasberg,
  • Ronald G. Blasberg,
  • Ronald G. Blasberg

DOI
https://doi.org/10.3389/fimmu.2022.880959
Journal volume & issue
Vol. 13

Abstract

Read online

Response to immunotherapy across multiple cancer types is approximately 25%, with some tumor types showing increased response rates compared to others (i.e. response rates in melanoma and non-small cell lung cancer (NSCLC) are typically 30-60%). Patients whose tumors are resistant to immunotherapy often lack high levels of pre-existing inflammation in the tumor microenvironment. Increased tumor glycolysis, acting through glucose deprivation and lactic acid accumulation, has been shown to have pleiotropic immune suppressive effects using in-vitro and in-vivo models of disease. To determine whether the immune suppressive effect of tumor glycolysis is observed across human solid tumors, we analyzed glycolytic and immune gene expression patterns in multiple solid malignancies. We found that increased expression of a glycolytic signature was associated with decreased immune infiltration and a more aggressive disease across multiple tumor types. Radiologic and pathologic analysis of untreated estrogen receptor (ER)-negative breast cancers corroborated these observations, and demonstrated that protein expression of glycolytic enzymes correlates positively with glucose uptake and negatively with infiltration of CD3+ and CD8+ lymphocytes. This study reveals an inverse relationship between tumor glycolysis and immune infiltration in a large cohort of multiple solid tumor types.

Keywords